Does lithium therapy cause parathyroid hormone (PTH)-dependent hypercalcemia?

Does Lithium Cause PTH-Dependent Hypercalcemia?

Yes, lithium therapy causes PTH-dependent hypercalcemia through both acute reversible mechanisms and chronic irreversible parathyroid hyperplasia, resulting in a clinical picture identical to primary hyperparathyroidism.

Mechanism and Clinical Presentation

Lithium induces hypercalcemia through two distinct pathophysiological pathways 1, 2:

Acute Effects (Potentially Reversible)

• Lithium acts on the calcium-sensing receptor (CaSR) pathway, shifting the set point for PTH secretion
• Creates a biochemical picture similar to familial hypocalciuric hypercalcemia (FHH)
• May resolve with lithium discontinuation in selected cases 3

Chronic Effects (Usually Irreversible)

• Permanent parathyroid gland changes occur with long-term therapy
• Either unmasks subclinical parathyroid adenomas or initiates multiglandular hyperparathyroidism
• Results in true primary hyperparathyroidism with elevated PTH and calcium 2
• Characterized by high prevalence of multiglandular disease (51.28%) 4

Prevalence and Risk

The most recent meta-analysis 4 demonstrates:

• Pooled prevalence of lithium-associated hypercalcemia: 3.17% (total calcium) to 4.23% (ionized calcium)
• This is approximately 8-fold higher than the 0.5% prevalence in the general population
• 19-year incidence of hyperparathyroidism: 6.3%, significantly elevated in females 5
• Among hypercalcemic patients screened, 91.7% test positive for primary hyperparathyroidism 6

Diagnostic Approach

The critical issue is severe underdiagnosis and undertreatment 6:

1. Baseline screening before lithium initiation: Measure calcium and PTH 3

2. During lithium therapy: Monitor calcium periodically (specific intervals not established, but at minimum annually given 3-4% prevalence)

3. If hypercalcemia detected (calcium ≥10.2 mg/dL):

   • Measure PTH immediately
   • Check phosphorus (expect low-normal due to PTH phosphaturic effect) 7
   • Measure 24-hour urine calcium (typically elevated, unlike FHH)
   • Assess renal function (creatinine/eGFR)
   • Check vitamin D status

4. Biochemical pattern of lithium-associated hyperparathyroidism:

   • Elevated calcium with elevated or inappropriately normal PTH
   • Low-normal phosphorus
   • Elevated or normal urine calcium (may be normal if vitamin D deficient or renal insufficient) 8

Management Algorithm

Step 1: Assess Severity and Psychiatric Stability

Mild asymptomatic hypercalcemia (calcium 10.2-11.0 mg/dL):

• Evaluate psychiatric stability and feasibility of lithium discontinuation 3
• Most patients have mild asymptomatic disease 3

Moderate to severe hypercalcemia (calcium >11.0 mg/dL) or symptomatic:

• Proceed directly to definitive treatment planning

Step 2: Trial of Lithium Discontinuation (Selected Cases Only)

Consider discontinuation trial if:

• Mild hypercalcemia
• Psychiatrically stable with alternative mood stabilizer available
• Short duration of lithium therapy
• Patient preference

Evidence shows:

• Anecdotal cases of resolution exist 3
• However, hypercalcemia often persists after discontinuation 5
• In one study, calcium remained elevated 8.5 weeks after stopping lithium 5
• Most patients require definitive treatment regardless of lithium status

Step 3: Definitive Treatment

Parathyroidectomy 9, 4:

• Recommended for persistent hyperparathyroidism regardless of lithium continuation
• Preoperative imaging (sestamibi, ultrasound) to localize adenoma(s)
• Critical consideration: High rate of multiglandular disease (51.28%) requires experienced surgeon 4
• Bilateral neck exploration often necessary given multiglandular prevalence 9
• Intraoperative PTH monitoring recommended to confirm adequate resection 9
• Success rate high when appropriately performed 4

Cinacalcet (calcimimetic) 9, 4:

• Effective alternative when surgery contraindicated or refused
• Reduces calcium by average 0.4 mmol/L
• Normalizes calcium in ~75% of patients
• Dose: Start 60 mg/day in 2 doses, titrate up to 270 mg/day in 3 doses as needed 9
• Limitation: Less effective at normalizing PTH; primarily controls calcium 9
• Common side effects: nausea (28%), muscle spasm, weakness 9

Bisphosphonates:

• Limited role; only transient calcium reduction 9
• Not recommended as primary therapy

Critical Clinical Pitfalls

1. Underscreening: 74.7% of hypercalcemic lithium patients receive no PTH evaluation 6

2. Underreferral: Only 13% of confirmed lithium-associated hyperparathyroidism cases are referred for surgery 6

3. Assuming reversibility: Most cases do not resolve with lithium discontinuation alone 5

4. Underestimating multiglandular disease: Standard unilateral exploration may fail given 51% multiglandular prevalence 4

5. Confounding factors masking diagnosis 10:

   • Vitamin D deficiency (limits calcitriol production, may normalize calcium/urine calcium)
   • Renal insufficiency (reduces hypercalciuria)
   • Low calcium diet
   • These factors may mask hypercalcemia while hyperparathyroidism progresses

Long-term Consequences

Untreated lithium-associated hyperparathyroidism leads to 7:

• Nephrocalcinosis and renal lithiasis (from hypercalciuria)
• Osteoporosis and pathologic fractures (from excessive bone resorption)
• Progressive renal dysfunction (isostenuria more common with hyperparathyroidism) 5
• Potential for brown tumors in severe cases 7

The combination of lithium's direct renal toxicity and hyperparathyroidism-induced hypercalciuria creates compounded renal risk 5.

Monitoring Protocol Recommendation

Given the evidence, establish institutional protocols for:

• Baseline: Calcium, PTH before lithium initiation
• Ongoing: Calcium every 6-12 months during lithium therapy
• If calcium ≥10.2 mg/dL: Immediate PTH, phosphorus, 24-hour urine calcium, vitamin D, creatinine
• If PTH elevated with hypercalcemia: Endocrinology/endocrine surgery referral 6

4, 6, 11, 3, 5, 2